Koszela Kamil, Woldańska-Okońska Marta, Skoczylas Agnieszka, Słupiński Michał, Gasik Robert
Department of Neuroorthopedics and Neurology Clinic and Polyclinic, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Department of Internal Medicine, Rehabilitation and Physical Medicine, Medical University of Lodz, Poland.
Reumatologia. 2025 Apr 14;63(3):159-165. doi: 10.5114/reum/200192. eCollection 2025.
Thoracic spine pain syndrome is far less common than lumbosacral or cervical pain. This pathology is often caused by work-related overload, especially sedentary work, lack of regular sport activities, and adopting incorrect postures. Thoracic spine pain may result, for instance, from degenerative joint lesions. In consequence, there is a reflex contraction of the soft, paraspinal tissues (muscles, fascia, ligaments). In this case, one of the treatment methods is spinal mesotherapy. The purpose of the present research was to evaluate the effectiveness and safety of thoracic spinal mesotherapy with collagen type I vs. lignocaine.
A retrospective analysis of the results of the treatment of patients with chronic thoracic back pain syndrome using mesotherapy was performed. A total of 130 patients (49 men and 81 women; mean age: 49 ±9 years) were divided into 2 groups: group A ( = 65), treated with collagen type I, and group B ( = 65), treated with lignocaine 1%. Mesotherapy was performed weekly over 5 weeks. Patients were assessed using the Visual Analogue Scale (VAS) and Laitinen scales before the therapy, after the therapy, and after a 3-month follow-up visit.
A statistically significant improvement was observed after the use of thoracic spinal mesotherapy both with collagen type I and lignocaine, on the VAS and Laitinen scales, with the collagen treatment having better results at the 3-month follow-up visit. No adverse effects were observed after the procedures.
Spinal mesotherapy is an effective and safe method of treating chronic thoracic back pain syndrome using collagen type I and lignocaine. However, in an average observation, collagen mesotherapy seems to be more effective.
胸椎疼痛综合征远比腰骶部或颈部疼痛少见。这种病症通常由工作相关的负荷过重引起，尤其是久坐工作、缺乏规律的体育活动以及采取不正确的姿势。例如，胸椎疼痛可能源于退行性关节病变。结果，椎旁软组织（肌肉、筋膜、韧带）会出现反射性收缩。在这种情况下，一种治疗方法是脊柱中胚层疗法。本研究的目的是评估使用I型胶原蛋白与利多卡因进行胸椎中胚层疗法的有效性和安全性。
对使用中胚层疗法治疗慢性胸背部疼痛综合征患者的结果进行回顾性分析。总共130名患者（49名男性和81名女性；平均年龄：49±9岁）被分为两组：A组（n = 65），接受I型胶原蛋白治疗；B组（n = 65），接受1%利多卡因治疗。中胚层疗法每周进行一次，共进行5周。在治疗前、治疗后以及3个月的随访后，使用视觉模拟量表（VAS）和莱蒂宁量表对患者进行评估。
在VAS和莱蒂宁量表上，使用I型胶原蛋白和利多卡因进行胸椎中胚层疗法后均观察到统计学上的显著改善，在3个月的随访中，胶原蛋白治疗效果更好。治疗后未观察到不良反应。
脊柱中胚层疗法是使用I型胶原蛋白和利多卡因治疗慢性胸背部疼痛综合征的一种有效且安全的方法。然而，在一般观察中，胶原蛋白中胚层疗法似乎更有效。
